Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 224

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 224
---
 The Company received net cash proceeds of approximately $ 3.5million and issuance costs of $ 0.3million. The shares of common stock issued from the exercise of the Class D Common Stock Warrants were registered on Form S-1 and declared effective by the SEC on January 31, 2024. The Class E Common Stock Warrants offered in the private placement were registered on Form S-3 with the SEC and declared effective on September 12, 2024. Class E Warrant Inducement On December 3, 2024, the Company entered into warrant exercise inducement offer letters with certain holders of the Class E Common Stock Warrants exercisable for an aggregate of 254,002shares of common stock with an exercise price of $ 16.00per share. In exchange, the Company agreed to issue Class F Common Stock Warrants exercisable for 254,002shares of its common stock and Class G Common Stock Warrants exercisable for 381,004shares of its common stock (see Note 9). The warrant inducement was considered a private placement pursuant to Section 4(a)(2) of the Securities Act. In connection with the warrant inducement, the Company agreed to pay Roth a cash fee of $ 325,000for its services, in addition to reimbursement for certain expenses. The Company received net cash proceeds of approximately $ 3.7million and issuance costs of $ 0.4million. The shares of common stock issued from the exercise of the Class E Common Stock Warrants were registered on Form S-3, which was declared effective by the SEC on September 12, 2024. The Class F Common Stock Warrants and Class G Common Stock Warrants offered in the private placement were registered on Form S-3, which was declared effective on December 20, 2024. 6. Preferred Stock The Company is authorized under its articles of incorporation, as amended, up to 5,000,000shares of preferred stock, which may be issued as designated by the Board of Directors without stockholder approval. As of March 31, 2025, there were noshares of preferred stock issued and outstanding. F-35

7. Common Stock

The Company is authorized under its articles of
incorporation, as amended, to issue up to shares of common stock, par value $ per share.

Common Stock Issuance during the year ended December 31, 2024

On January 29,